1 – 10 of 11
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2021
-
Mark
Sustained Remission in Patients With Rheumatoid Arthritis Receiving Triple Therapy Compared to Biologic Therapy : A Swedish Nationwide Register Study
(
- Contribution to journal › Article
- 2017
-
Mark
Treatment with belimumab in systemic lupus erythematosus does not impair antibody response to 13-valent pneumococcal conjugate vaccine.
(
- Contribution to journal › Article
- 2015
-
Mark
Development of functional impairment and disability in rheumatoid arthritis patients followed for 20 years - relation to disease activity, joint damage and comorbidity.
(
- Contribution to journal › Article
-
Mark
The risk of pneumococcal infections after immunization with pneumococcal conjugate vaccine compared to non-vaccinated inflammatory arthritis patients.
(
- Contribution to journal › Article
-
Mark
The association between antibody levels before and after 7-valent pneumococcal conjugate vaccine immunization and subsequent pneumococcal infection in chronic arthritis patients.
(
- Contribution to journal › Article
- 2014
-
Mark
Predictors of work disability during the first 3 years after diagnosis in a national rheumatoid arthritis inception cohort.
(
- Contribution to journal › Article
- 2013
-
Mark
Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in early rheumatoid arthritis: 2-year quality-of-life results of the randomised, controlled, SWEFOT trial.
(
- Contribution to journal › Article
- 2011
-
Mark
National EQ-5D tariffs and quality-adjusted life-year estimation: comparison of UK, US and Danish utilities in south Swedish rheumatoid arthritis patients.
(
- Contribution to journal › Article
- 2007
-
Mark
Influenza vaccination as model for testing immune modulation induced by anti-TNF and methotrexate therapy in rheumatoid arthritis patients.
(
- Contribution to journal › Article
-
Mark
Treatment with TNF-blockers and mortality risk in patients with rheumatoid arthritis.
(
- Contribution to journal › Article